Skip to content
A new biomarker for cognitive dysfunction in SLE? episode artwork

Feb 2, 2022 16 min

A new biomarker for cognitive dysfunction in SLE?

from BMJ talk medicine Hosted by BMJ Group

Duane Peters from the Lupus Foundation of America interviews Dr Erik Anderson and Dr Meggan Mackay from the Feinstein Institutes for Medical Research in New York in the USA. They discuss their study into imbalances in quinolinic acid and kynurenic acid levels in the brain in SLE patients, and propose that the ratio between these two metabolites could be used as a new biomarker or therapeutic target for cognitive dysfunction. Access the paper here: https://lupus.bmj.com/content/8/1/e000559

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

A new biomarker for cognitive dysfunction in SLE?

0:00 16:00

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of BMJ talk medicine?

This episode is 16 minutes long.

When was this BMJ talk medicine episode published?

This episode was published on February 2, 2022.

Can I download this BMJ talk medicine episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.